Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies.

Journal Article (Journal Article)

Cigarette smoking is associated with an increased risk of developing mucinous ovarian tumors but whether it is associated with ovarian cancer survival overall or for the different histotypes is unestablished. Furthermore, it is unknown whether the association between cigarette smoking and survival differs according to strata of ovarian cancer stage at diagnosis. In a large pooled analysis, we evaluated the association between various measures of cigarette smoking and survival among women with epithelial ovarian cancer. We obtained data from 19 case-control studies in the Ovarian Cancer Association Consortium (OCAC), including 9,114 women diagnosed with ovarian cancer. Cox regression models were used to estimate adjusted study-specific hazard ratios (HRs), which were combined into pooled hazard ratios (pHR) with corresponding 95% confidence intervals (CIs) under random effects models. Overall, 5,149 (57%) women died during a median follow-up period of 7.0 years. Among women diagnosed with ovarian cancer, both current (pHR = 1.17, 95% CI: 1.08-1.28) and former smokers (pHR = 1.10, 95% CI: 1.02-1.18) had worse survival compared with never smoking women. In histotype-stratified analyses, associations were observed for mucinous (current smoking: pHR = 1.91, 95% CI: 1.01-3.65) and serous histotypes (current smoking: pHR = 1.11, 95% CI: 1.00-1.23; former smoking: pHR = 1.12, 95% CI: 1.04-1.20). Further, our results suggested that current smoking has a greater impact on survival among women with localized than disseminated disease. The identification of cigarette smoking as a modifiable factor associated with survival has potential clinical importance as a focus area to improve ovarian cancer prognosis.

Full Text

Duke Authors

Cited Authors

  • Praestegaard, C; Jensen, A; Jensen, SM; Nielsen, TSS; Webb, PM; Nagle, CM; DeFazio, A; Australian Ovarian Cancer Study Group, ; Høgdall, E; Rossing, MA; Doherty, JA; Wicklund, KG; Goodman, MT; Modugno, F; Moysich, K; Ness, RB; Edwards, R; Matsuo, K; Hosono, S; Goode, EL; Winham, SJ; Fridley, BL; Cramer, DW; Terry, KL; Schildkraut, JM; Berchuck, A; Bandera, EV; Paddock, LE; Massuger, LF; Wentzensen, N; Pharoah, P; Song, H; Whittemore, A; McGuire, V; Sieh, W; Rothstein, J; Anton-Culver, H; Ziogas, A; Menon, U; Gayther, SA; Ramus, SJ; Gentry-Maharaj, A; Wu, AH; Pearce, CL; Pike, M; Lee, AW; Sutphen, R; Chang-Claude, J; Risch, HA; Kjaer, SK; Ovarian Cancer Association Consortium,

Published Date

  • June 1, 2017

Published In

Volume / Issue

  • 140 / 11

Start / End Page

  • 2422 - 2435

PubMed ID

  • 28063166

Pubmed Central ID

  • PMC5489656

Electronic International Standard Serial Number (EISSN)

  • 1097-0215

Digital Object Identifier (DOI)

  • 10.1002/ijc.30600


  • eng

Conference Location

  • United States